Wei Luan,Wen-Xin Li. Safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma and pleural effusion. Oncol Transl Med, 2018, 4: 10-12.
Safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma and pleural effusion
Received:January 07, 2018  Revised:March 29, 2018
View Full Text  View/Add Comment  Download reader
KeyWord:renal cell carcinoma; pleural effusion; multi-kinase inhibitor; endostar
Author NameAffiliationE-mail
Wei Luan Departments of Oncology,Inner Mongolia people's Hospital luan1977@126.com 
Wen-Xin Li Departments of Oncology,Inner Mongolia people's Hospital liwenxin1888@sohu.com 
Hits: 402
Download times: 638
Abstract:
      Objective The aim of this study was to evaluate the safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma (mRCC) and pleural effusion. Methods A total of 10 patients with mRCC (8 clear-cell RCCs, 1 papillary RCC, 1 chromophobe RCC) with pleural effusion from January 2014 to October 2015 were recruited. Four patients received sorafenib (400 mg, twice daily), while six received sunitinib (50 mg, once daily; 2 weeks on and 1 week off). All patients received multi-kinase inhibitor plus pleural cavity perfusion of endostar (15 mg on days 1–4 for 1 or 2 weeks). Results The response rate of pleural effusion was 70%. Adverse reactions were limited and mild. Conclusion The regimen of multi-kinase inhibitor plus pleural cavity perfusion of endostar was both effective and safe for the treatment of patients with mRCC with pleural effusion, and may control local symptoms.
Close